```html

Glottic Cancer – A Comprehensive Medical Guide

Overview

Glottic cancer is a type of head‑and‑neck malignancy that originates in the glottis, the portion of the larynx (voice box) that contains the vocal cords. The disease is most commonly classified as a subset of laryngeal squamous cell carcinoma (LSCC), accounting for roughly 60‑70% of all laryngeal cancers.<sup>[1]</sup>

Who it affects

• Age: The median age at diagnosis is 60‑65 years.
• Gender: Men are about 4‑5 times more likely to develop glottic cancer than women.
• Geography: Incidence is highest in North America and Europe; lower rates are reported in parts of Asia and Africa where tobacco use is less prevalent.

Prevalence

According to the International Agency for Research on Cancer (IARC), there were an estimated 13,000 new cases of glottic cancer in the United States in 2023, representing ≈ 2% of all cancer diagnoses.<sup>[2]</sup> The 5‑year survival rate varies dramatically by stage—about 90% for early (stage I‑II) disease but drops to <40% for advanced (stage III‑IV) disease.

Symptoms

Early glottic cancer often presents subtly, which can delay diagnosis. Below is a comprehensive list of possible signs and symptoms.

Voice Changes (Dysphonia)

• Hoarseness or a “raspy” voice lasting more than two weeks.
• Early fatigue of the voice after speaking.

Throat‑Related Symptoms

• Sore throat that does not improve with typical remedies.
• Feeling of a foreign body or “lump” in the throat.
• Persistent cough, especially one that is dry.

Airway Symptoms

• Wheezing or stridor (high‑pitched breathing sound).
• Shortness of breath on exertion.

Swallowing Problems (Dysphagia)

• Difficulty swallowing solids or liquids.
• Painful swallowing (odynophagia).

Neck and Ear Symptoms

• Painless swelling of lymph nodes in the neck (more common with advanced disease).
• Referred ear pain (earache without ear infection).

Systemic Symptoms (usually late)

• Unintended weight loss.
• Fatigue.
• Night sweats or low‑grade fevers.

Because many of these signs overlap with benign conditions (e.g., laryngitis, reflux), any persistent symptom lasting > 2‑3 weeks should prompt a medical evaluation.

Causes and Risk Factors

Glottic cancer is primarily a squamous cell carcinoma caused by genetic mutations in the epithelial cells of the vocal cords. The mutations are usually induced by chronic exposure to carcinogens.

Major Risk Factors

• Tobacco use – Smoking cigarettes, cigars, or pipe tobacco accounts for ~ 85% of cases.<sup>[3]</sup> The risk rises with pack‑years.
• Alcohol consumption – Heavy, chronic drinking synergistically multiplies the smoking risk (up to 15‑fold).
• Human papillomavirus (HPV) – While HPV is a stronger risk for supraglottic cancers, certain high‑risk strains (HPV‑16) have been linked to a minority of glottic tumors.
• Occupational exposures – Asbestos, wood dust, metal fumes, and certain chemicals (e.g., nickel, formaldehyde).
• Gastroesophageal reflux disease (GERD) – Chronic acid exposure may irritate the laryngeal mucosa.
• Dietary factors – Low intake of fruits/vegetables and high consumption of processed meats.
• Age and gender – Risk increases with age; males are more affected due to higher historic smoking rates.

Genetic and Molecular Contributors

Common genetic alterations include mutations in the TP53 tumor suppressor gene and amplifications of the EGFR (epidermal growth factor receptor) pathway. These changes drive uncontrolled cell growth and are targets for newer systemic therapies.

Diagnosis

Accurate staging is essential because treatment choices differ dramatically between early‑stage (confined to the vocal cords) and advanced disease (spread to cartilage, tissue, or distant sites).

Clinical Evaluation

• History & Physical Exam – Detailed symptom chronology, smoking/alcohol history, occupational exposures.
• Neck palpation – Assess for enlarged cervical lymph nodes.

Imaging Studies

• Flexible nasolaryngoscopy – Direct visualization of the vocal cords; allows biopsy.
• Laryngeal stroboscopy – Uses a flashing light to assess vocal cord vibration and subtle lesions.
• Computed tomography (CT) of neck – Evaluates cartilage invasion, subglottic extension, and nodal disease.
• Magnetic resonance imaging (MRI) – Preferred for soft‑tissue detail, especially pre‑laryngeal cartilage.
• Positron emission tomography (PET)/CT – Recommended for stage III‑IV disease to detect distant metastasis.

Pathologic Confirmation

A tissue sample is mandatory for definitive diagnosis.

• Biopsy – Performed during direct laryngoscopy under general anesthesia; the specimen is sent for histopathology.
• Histology – Typically reveals squamous cell carcinoma; grading (well, moderately, poorly differentiated) influences prognosis.

Staging System

The American Joint Committee on Cancer (AJCC) 8th edition uses the TNM system:

• T – Size and extent of the primary tumor (T1‑T4).
• N – Regional lymph node involvement (N0‑N3).
• M – Distant metastasis (M0 or M1).

Treatment Options

Treatment is individualized based on stage, voice preservation goals, comorbidities, and patient preference.

Early‑Stage Disease (T1‑T2, N0)

• Radiation therapy (RT) – Standard dose 66‑70 Gy in 33‑35 fractions; yields > 90% local control with good voice outcomes.
• Transoral laser microsurgery (TLM) – Precise removal using a CO₂ laser; preserves voice and may be repeated if recurrence occurs.
• Single‑session photodynamic therapy (PDT) – An emerging option for small, superficial lesions.

Locally Advanced Disease (T3‑T4, N+)

• Concurrent chemoradiotherapy (CRT) – Radiation plus cisplatin (100 mg/m² every 3 weeks) is the cornerstone for organ preservation.
• Total or partial laryngectomy – Surgical removal of part or all of the larynx when radiation is contraindicated or after failed CRT.
• Neck dissection – Performed if clinically positive lymph nodes are present.

Systemic Therapies (for recurrent/metastatic disease)

• Targeted agents – EGFR inhibitors (cetuximab) for tumors expressing EGFR.
• Immunotherapy – PD‑1 inhibitors (pembrolizumab, nivolumab) have shown durable responses in checkpoint‑inhibitor‑eligible patients.
• Platinum‑based chemotherapy – Carboplatin or cisplatin combined with 5‑fluorouracil (5‑FU) for palliative intent.

Supportive and Lifestyle Interventions

• Smoking cessation programs (counseling, nicotine replacement, varenicline).
• Alcohol moderation or abstinence.
• Speech‑language pathology (SLP) for voice rehabilitation before and after treatment.
• Nutrition counseling to maintain weight during radiation.

Living with Glottic Cancer

Managing life after diagnosis involves physical, emotional, and practical considerations.

Voice Care

• Follow SLP exercises to improve breath support and reduce strain.
• Avoid whispering (it stresses vocal folds).
• Stay hydrated; use a humidifier in dry environments.

Nutrition

• Soft, high‑protein foods (smoothies, soups, Greek yogurt) are easier to swallow during radiation.
• Supplement with vitamins and minerals if appetite declines.

Follow‑up Schedule

• First 2 years: Laryngoscopic exam every 3‑6 months.
• Years 3‑5: Every 6‑12 months.
• After 5 years: Annual review, unless symptoms recur.

Psychosocial Support

• Join support groups for head‑and‑neck cancer patients.
• Consider counseling for anxiety, depression, or body‑image concerns.
• Engage family in care planning to share responsibilities.

Rehabilitation

• Physical therapy for neck mobility after surgery.
• Swallowing therapy if dysphagia persists.
• Respiratory exercises to improve stamina.

Prevention

Because most cases are linked to modifiable exposures, primary prevention is effective.

• Quit tobacco – Benefits begin within weeks; risk drops by 50% after 10 years of abstinence.
• Limit alcohol – No more than 1 drink per day for women, 2 for men.
• Vaccinate against HPV – The 9‑valent vaccine protects against high‑risk strains linked to head‑and‑neck cancers.
• Use protective equipment – Respirators or masks in occupations with wood dust, asbestos, or metal fumes.
• Manage reflux – Lifestyle changes (elevate head of bed, avoid late meals) and proton‑pump inhibitors if needed.
• Regular medical check‑ups – Annual ENT exam for high‑risk individuals (long‑term smokers, heavy drinkers).

Complications

If left untreated or if treatment fails, several serious complications can arise.

• Airway obstruction – Tumor growth can block the glottic opening, leading to stridor and respiratory distress.
• Permanent voice loss – Extensive disease may destroy both vocal cords.
• Aspiration pneumonia – Swallowing dysfunction permits food/liquid to enter the lungs.
• Neck metastasis – Spread to cervical lymph nodes worsens prognosis.
• Second primary tumors – Patients with head‑and‑neck cancer have an elevated risk of developing another malignancy, especially in the lung or esophagus.
• Psychological distress – Chronic voice changes can affect social interaction and employment.

When to Seek Emergency Care

References

1. American Cancer Society. “Laryngeal Cancer.” 2023. https://www.cancer.org/cancer/laryngeal-cancer.html
2. International Agency for Research on Cancer (IARC). “GLOBOCAN 2023: Larynx Cancer Statistics.” 2024. https://gco.iarc.fr/
3. Mayo Clinic. “Laryngeal Cancer – Risk factors.” 2024. https://www.mayoclinic.org/diseases-conditions/laryngeal-cancer/symptoms-causes/syc-20374370
4. Cleveland Clinic. “Glottic Cancer Treatment Options.” 2024. https://my.clevelandclinic.org/health/diseases/15844-glottic-cancer
5. National Comprehensive Cancer Network (NCCN). “NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers.” Version 2.2024.
6. World Health Organization. “HPV Vaccines and Head and Neck Cancer.” 2023. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cancers

```